Merck KGaA shrinks U.S. research team as layoffs continue to batter industry

If you thought that biopharma layoffs would stay a cruel fad of 2022, you would, unfortunately, be mistaken. Merck KGaA is the latest company to downsize, shrinking its U.S. research wing by more than 100 employees.

Merck's layoffs mark at least the ninth recorded so far in the new year, more than the eight tallied in January 2022 and there’s still a week to go in the month.